Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $17.17 Consensus PT from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $17.1667.

Several brokerages recently issued reports on KPTI. HC Wainwright restated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Thursday, June 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Karyopharm Therapeutics in a research report on Tuesday, June 9th. Robert W. Baird dropped their price target on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 25th. Piper Sandler restated an “overweight” rating and issued a $16.00 price target (up from $8.00) on shares of Karyopharm Therapeutics in a research report on Monday, April 27th. Finally, Rodman & Renshaw upgraded Karyopharm Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Corient Private Wealth LLC purchased a new stake in Karyopharm Therapeutics in the 4th quarter valued at approximately $74,000. Baird Financial Group Inc. purchased a new stake in Karyopharm Therapeutics in the 2nd quarter valued at approximately $45,000. Hsbc Holdings PLC purchased a new stake in Karyopharm Therapeutics in the 1st quarter valued at approximately $66,000. Tudor Investment Corp ET AL purchased a new stake in Karyopharm Therapeutics in the 4th quarter valued at approximately $95,000. Finally, XTX Topco Ltd purchased a new stake in Karyopharm Therapeutics in the 2nd quarter valued at approximately $56,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Stock Up 7.2%

Shares of KPTI stock opened at $9.65 on Wednesday. The stock has a market capitalization of $218.67 million, a PE ratio of -0.64 and a beta of 0.83. Karyopharm Therapeutics has a 52-week low of $3.65 and a 52-week high of $10.99. The stock’s 50-day moving average price is $8.79 and its 200 day moving average price is $7.87.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.45) by $0.21. The company had revenue of $35.07 million during the quarter, compared to analyst estimates of $31.40 million. Analysts expect that Karyopharm Therapeutics will post -3.24 earnings per share for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.